AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sanofi Director's Dealing 2016

Feb 3, 2016

1643_dirs_2016-02-03_a00c5f3d-a1ec-4c85-b37e-2d9e673d7329.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK: 0001178670
Period of Report: 2016-02-01

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-02-01	Common Stock	P	205030	$69.75	Acquired	10256633	Indirect

Footnotes

F1: Purchase of shares in accordance with the terms of the investor agreement between Alnylam and Genzyme (a Sanofi company) dated February 27, 2014.